You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic ncc Renal Cell Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • 68Ga-NY104 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 18, 2023

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Renal Cell Carcinoma Trial (Cytoreductive Nephrectomy)

Not yet recruiting
  • Renal Cell Carcinoma
  • Cytoreductive Nephrectomy
  • (no location specified)
Jul 3, 2023

Carcinoma, Renal Cell Trial (Orellanine)

Not yet recruiting
  • Carcinoma, Renal Cell
  • (no location specified)
Jan 25, 2023

Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma Trial in Chengdu (AK104, Axitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +3 more
  • Chengdu, Sichuan, China
    West China Hospital
Apr 10, 2023

Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Boston (Implantable Microdevice (IMD))

Not yet recruiting
  • Renal Cell Carcinoma
  • +2 more
  • Implantable Microdevice (IMD)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 17, 2023

Renal Cell Carcinoma Trial in Beijing, Seoul (RO7247669, Tiragolumab, Pembrolizumab)

Recruiting
  • Renal Cell Carcinoma
  • Beijing, China
  • +1 more
Mar 28, 2023

Metastatic and/or Advanced Renal Cell Carcinoma, Treated With

Completed
Has Results
  • Carcinoma
  • Renal Cell
  • London, United Kingdom
    Pfizer UK
Jan 9, 2023

Learn About First and Later Lines of Medicines in Treating

Completed
  • Metastatic Renal Cell Carcinoma
    • New York, New York
      Pfizer Headquarters
    May 12, 2023

    Primary and Metastatic Tumors in Renal Cell Carcinoma and

    Recruiting
    • Renal Cell Carcinoma
    • +4 more
    • Immune checkpoint inhibitor targeting PD1
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center - Philadelphia
    Jan 27, 2023

    Metastatic Renal Cell Carcinoma Trial in Cleveland (Nivolumab, Ipilimumab)

    Active, not recruiting
    • Metastatic Renal Cell Carcinoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
    Jan 25, 2023

    Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma Trial in Duarte

    Recruiting
    • Advanced Clear Cell Renal Cell Carcinoma
    • +11 more
    • Cabozantinib S-malate
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Nov 22, 2022

    Kidney Cancer, Clear Cell Renal Cell Carcinoma Metastatic, Synchronous Tumor Trial in Seoul (Cytoreductive

    Recruiting
    • Kidney Cancer
    • +2 more
    • Cytoreductive nephrectomy±metastasectomy
    • Human-derived materials sampling
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Mar 2, 2023

    Non-Clear Cell Renal Cell Carcinoma Trial in Duarte (XL092, Nivolumab, Sunitinib Malate)

    Recruiting
    • Non-Clear Cell Renal Cell Carcinoma
    • Duarte, California
      Exelixis Clinical Site #1
    Jan 13, 2023

    Metastatic Renal Cell Carcinoma Trial in France (Cabozantinib)

    Recruiting
    • Metastatic Renal Cell Carcinoma
    • Angers, France
    • +8 more
    Dec 5, 2022

    Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic Trial in Iowa City (Selenomethionine (SLM),

    Recruiting
    • Clear Cell Renal Cell Carcinoma
    • Clear Cell Renal Cell Carcinoma Metastatic
    • Selenomethionine (SLM)
    • +2 more
    • Iowa City, Iowa
      University of Iowa Hospitals & Clinics
    Sep 19, 2022

    Multiomics Approach in Metastatic Clear Renal Cell Carcnoma

    Recruiting
    • Metastatic Clear Cell Renal Carcinoma
    • CT scan
    • Plasma collection
    • Milan, Mi, Italy
      Istituto Tumori
    Mar 13, 2023

    Renal Cell Carcinoma Trial in Houston (Perfusion CT scan)

    Active, not recruiting
    • Renal Cell Carcinoma
    • Perfusion CT scan
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 6, 2022

    Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Tumor Trial in Houston (procedure,

    Active, not recruiting
    • Bladder Urothelial Carcinoma
    • +4 more
    • Biopsy
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 18, 2022

    go Back Into Records and Observe How People With Metastatic

    Not yet recruiting
    • Carcinoma, Renal Cell
    • Clear-cell Metastatic Renal Cell Carcinoma
    • Istanbul, Turkey
      Pfizer
    Feb 15, 2023

    Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma Trial in London (Savolitinib, MEDI4736, Tremelimumab)

    Active, not recruiting
    • Renal Clear Cell Carcinoma
    • Renal Papillary Cell Carcinoma
    • London, United Kingdom
      Thomas Powles
    Aug 10, 2022

    Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1

    Not yet recruiting
    • Metastatic Clear Cell Renal Cell Carcinoma
    • With Positive PSMA Expression at Tumor Sites
    • 177Lu-PSMA-1 (radiopharmaceutical)
    • (no location specified)
    Sep 26, 2023

    Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

    Not yet recruiting
    • Urothelial Carcinoma
    • +2 more
    • (no location specified)
    Dec 15, 2022